Clinical trials: Pancreas Tumor
Pancreatic Cancer
Becotatug Vedotin Plus Anti-PD-1 and S-1 in Patients With EGFR-Positive Advanced Pancreatic Cancer Who Have Failed at Least One Line of Standard Therapy
This is a prospective, single-arm, single-center exploratory clinical study. The purpose of this study is to evaluate the efficacy and safety of a triplet regimen-becotatug vedotin combined with anti-PD-1 and S-1-in patients with…
- Trial name
- NCT07892573
- Testing
- Becotatug Vedotin, Anti-PD-1 antibody, S-1
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Ningbo Medical Center Lihuili Hospital
Advanced Pancreatic Cancer
SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer
This is a prospective, multicenter, single arm clinical study. The main purpose of the study is to evaluate the clinical efficacy and safety of SBRT combined with Nimotuzumab and mono-chemotherapy in the treatment of locally…
- Trial name
- Nim-PC-28 (NCT06422156)
- Testing
- Stereotactic body radiation, Nimotuzumab, mono-chemotherapy
- Volunteers
- 73 people
- Sponsor
- Peking University Third Hospital
Pancreatic Neuroendocrine Tumors
Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neoplasms
To determine the efficacy and safety of robotic, laparoscopic and open surgery for enucleation of benign pancreatic neuroendocrine tumors
- Trial name
- NCT02125929
- Testing
- Robotic surgery, Laparoscopic surgery, Open surgery
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Peking Union Medical College Hospital
Diabetes Mellitus, Adult-Onset, Diabetes Complications
Pancreatic Cancer Can be Detected by Adrenomedullin in New Onset Diabetes Patients
Pancreatic Cancer is a leading cause of cancer-related death. To date, only one fifth of patients at diagnosis is presented resectable because the diagnosis is often delayed making the 5-year survival of this disease globally…
- Conditions
- Diabetes Mellitus, Adult-Onset, Diabetes Complications, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasm
- Trial name
- PaCANOD (NCT02456051)
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- University of Roma La Sapienza
Unresectable Pancreatic Cancer
Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.
This will a be an open label, multicentre, randomized, controlled study in patients with unresectable pancreatic cancer, locally advanced or metastatic, with significant weight loss, and the tumour located in the head of the…
- Trial name
- PERTseverance (NCT06099119)
- Testing
- creon 35.000 Ph.U (R), Best Standarard of Care
- Where
- 4 sites in Italy, Spain and 1 more
- Volunteers
- 100 people
- Sponsor
- Hospital Clinico Universitario de Santiago
Pancreatic Cancer
Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT
This study is being conducted to find out what effects (good and bad) that a combination of treatment with chemotherapy, radiation therapy and surgery has on you and your pancreatic cancer.
- Trial name
- NCT00761241
- Testing
- Gemcitabine, Docetaxel, 5FU, Oxaliplatin, Alpha-interferon, Abdominal/pelvic radiation therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Benaroya Research Institute
Pancreatic Cancer
Endoscopic Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer
This study aims to evaluate the EUS-RFA in terms of efficacy for pain management and improvement in quality-of-life parameters for patients with advanced inoperable pancreatic cancer.
- Trial name
- NCT05535894
- Testing
- Ablation of Celiac Ganglion
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- West Virginia University
Pancreatic Cancer, Surgery
Quality of Life in Elderly Patients After Pancreatic Cancer Surgery
Pancreatic cancer mainly affects the elderly, with over 85% of patients diagnosed after the age of 60 and over half after the age of 70.
- Conditions
- Pancreatic Cancer, Surgery, Elderly
- Trial name
- ADL_DPC_PA (NCT06079229)
- Testing
- Phone call
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Hospices Civils de Lyon
Pancreatic Cancer, Lymphadenopathy
Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle
The primary objective of this proposed prospective randomized, multi-center study is to evaluate the capability of the new 22G SharkCore™ needle to obtain tissue specimens and to compare its performance against the standard 22G…
- Conditions
- Pancreatic Cancer, Lymphadenopathy, Cholangiocarcinoma
- Trial name
- NCT02872831
- Testing
- 22G SharkCore™ needle, 22G BNX EUS-FNA Needle
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Pancreatic Cancer, Cancer of Pancreas
Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma
There are two parts to this study: the goal of the first part of the study is to find the best dose of tosedostat when given in combination with capecitabine.
- Conditions
- Pancreatic Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Cancer
- Trial name
- NCT02352831
- Testing
- Tosedostat, Capecitabine, Fresh tissue biopsy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Biliary Obstruction, Pancreas Neoplasm
EUS-guided Choledochoduodenostomy for Primary Drainage of Malignant Distal Biliary Obstruction
A prospective single-centre pilot study investigating the feasibility and safety of EUS-guided choledochostomy as primary drainage strategy in patients with distal malignant biliary obstruction using a FCSEMS through LAMS to…
- Conditions
- Biliary Obstruction, Pancreas Neoplasm, Distal Cholangiocarcinoma
- Trial name
- SCORPION-II-p (NCT05595122)
- Testing
- EUS-CDS
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Pancreatic Cancer, Pancreatic Cancer Non-resectable
Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer
To evaluate the efficacy and safety of surufatinib combined with gemcitabine plus nab-paclitaxel in patients with locally advance d pancreatic cancer
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Ductal Adenocarcinoma, PDAC
- Trial name
- NCT06361030
- Testing
- surufatinib combined with gemcitabine plus nab-paclitaxel
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the…
- Conditions
- Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant
- Trial name
- ALLELE (NCT03394365)
- Testing
- tabelecleucel
- Where
- 71 sites in United States, Australia and 7 more
- Volunteers
- 115 people
- Sponsor
- Pierre Fabre Medicament
Pancreas Neoplasms
DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer
The goal of this clinical trial is to estimate the antitumor response of mFOLFIRINOX + Dostarlimab + oral HD vitamin D3 in patients with non-pretreated histologically confirmed metastatic Stage IV adenocarcinoma of the pancreas.
- Trial name
- DOVIPA (NCT06757244)
- Testing
- Dostarlimab, Vitamin D3 (Cholecalciferol), mFOLFIRINOX Treatment Regimen
- Where
- 5 sites in France
- Volunteers
- 35 people
- Sponsor
- Hopital Foch
Neuroendocrine Tumors
Biomarker Study in Pancreatic Neuroendocrine Tumours
The biology of pancreatic neuroendocrine tumors can change during the disease course. This evolution of disease can manifest through increases in tumor proliferation rate, resistance to medical therapy and/or a change in tumor…
- Trial name
- PROGRESS (NCT03130205)
- Testing
- Core Needle Biopsy, Computed Tomography, 18F-FDG-PET
- Where
- Sweden
- Volunteers
- 30 people
- Sponsor
- Uppsala University
Pancreatic Cancer Resectable
Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.
This prospective and open-label study evaluates the efficacy and safety of mFOLFIRINOX as postoperative chemotherapy in treating Chinese patients with pancreatic cancer after R0/R1 resection.
- Trial name
- NCT04224402
- Testing
- mFOLFORINOX
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Yuhong Li
Pancreatic Neoplasms, DNA Methylation
Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples
The goal of this observational study is to test in patients with cystic tumor of pancreas. The main questions it aims to answer are: Screening of molecular diagnostic markers for pancreatic cystic tumors by cfDNA methylation…
- Conditions
- Pancreatic Neoplasms, DNA Methylation, Proteome
- Trial name
- NCT05737953
- Testing
- cfDNA methylation sequencing and proteome analysis
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhaoshen Li
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Pancreatic Cancer Recurrence in the Netherlands
The aim of this nationwide, observational cohort study is to evaluate current surveillance strategies after primary resection of pancreatic ductal adenocarcinoma (PDAC) in the Netherlands, with regard to the detection, treatment…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreas Cancer, PDAC
- Trial name
- NCT04605237
- Where
- Netherlands
- Volunteers
- 1,750 people
- Sponsor
- UMC Utrecht
Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours
A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)
This European, prospective, multicentre, double-blind randomised study will evaluate the effect of lanreotide (120 mg every 28 days until disease progression) versus placebo in patients with metastatic/locally advanced…
- Trial name
- REMINET (NCT02288377)
- Testing
- lanreotide
- Where
- 24 sites in Belgium, France and 2 more
- Volunteers
- 53 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Colorectal Cancer, Pancreatic Ductal Cancer
A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
The primary objectives of Part 1 of this study are to: Assess the safety and tolerability of the combination of BGB-3245 and panitumumab in participants with advanced or metastatic colorectal cancer (CRC) with a known mutation…
- Conditions
- Colorectal Cancer, Pancreatic Ductal Cancer, Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
- Trial name
- NCT06194877
- Testing
- BGB-3245, Panitumumab
- Where
- 5 sites in United States, Australia
- Volunteers
- 13 people
- Sponsor
- MapKure, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.